Cannabis-enriched enzymatically treated therapeutic composition

1. A therapeutic composition comprising:

(i) water at a concentration in the range of up to 30% by weight;

(ii) at least 30 wt % glucose;

(iii) at least 5 parts per million of a product of glucose oxidation selected from the group consisting of glucono-lactone, gluconic acid and combinations thereof;

(iv) a cannabinoid selected from the group consisting of THC, THCa, CBD, CBDa and combinations thereof at a concentration in the range of from at least 0.1 parts per million (ppm) to less than 20,000 ppm by weight;

(v) at least 1 part per million of a product of cannabinoid oxidation that can be produced from a same said cannabinoid selected from the group consisting of THC, THCa, CBD, CBDa and combinations thereof;

(vi) a honey enzyme;

optionally (vii) a terpene;

optionally (viii) at least 1 parts per million terpene oxidation product, and;

optionally a product of terpene oxidation,

wherein a glucose to glucose oxidation product weight/weight ratio is in the range of between 10 and 1000,

wherein a glucose to cannabinoid weight/weight ratio is greater than 10,

wherein a weight/weight ratio of said cannabinoid to said product of oxidation of said same cannabinoid is in the range of between 10 and 1000, and

wherein the composition is homogeneous.

2. The therapeutic composition of claim 1 , having an enhanced therapeutic effect compared with that of a composition comprising the same cannabinoid amounts, but not containing said product of glucose oxidation and not containing said cannabinoid reaction product and optionally not containing said terpene oxidation product.

3. The therapeutic composition of claim 2 , wherein said therapeutic effect, is for treating a condition selected from the group consisting of post trauma syndrome disorder (PTSD), anxiety, depression, psychosis syndromes, autism, Alzheimer's disease, Parkinson disease, inflammation, spasticity and muscle tension, pain, epilepsy, stroke, traumatic brain injury, bronchial disorders, cancer, drug abuse, Huntington's disease, Dystonia, Amyotrophic lateral sclerosis (ALS), Tourette syndrome, Myasthenia gravis, sleep disorders and skin related syndromes and inflammatory bowel disease.

4. A method of treating a medical condition selected from the group consisting of post trauma syndrome disorder (PTSD), anxiety, depression, psychosis syndromes, autism, Alzheimer's disease, Parkinson disease, inflammation, spasticity and muscle tension, pain, epilepsy, stroke, traumatic brain injury, bronchial disorders, cancer, drug abuse, Huntington's disease, Dystonia, Amyotrophic lateral sclerosis (ALS), Tourette syndrome, Myasthenia gravis, sleep disorders and skin related syndromes and inflammatory bowel disease, the method comprising administering to a subject an effective amount of the therapeutic composition of claim 1 .

5. A method for producing the therapeutic composition of claim 1 , comprising

(i) providing a glucose-containing composition;

(ii) providing a cannabinoid-containing composition;

(iii) blending said glucose-containing composition with said cannabinoid-containing composition to form cannabinoid-enriched glucose composition;

(iv) applying an enzyme at a selected temperature, a selected pH, and a selected water activity and for a selected duration, to said cannabinoid-enriched glucose composition, wherein said applying an enzyme comprises inducing enzyme activity and wherein said inducing comprises water addition, whereby an enzymatically-catalyzed conversion of at least one of glucose and cannabinoid is produced and optionally

(v) removing water from said cannabinoid-enriched glucose composition;

wherein said temperature, pH, water activity and duration are selected to enzymatically-catalyze the conversion of at least 0.1% by weight of said glucose, said cannabinoid or both.

6. The method of claim 5 , wherein said temperature, pH, and water activity are selected to reach the desired degree of conversion within a duration of less than a week.

7. The method of claim 5 , wherein said applied enzyme is a honey enzyme.

8. The method of claim 5 , wherein glucose to water weight/weight ratio in said cannabinoid-enriched glucose composition is greater than 2.

9. The method of claim 5 , wherein said glucose-containing composition additionally contains sucrose.

10. The method of claim 5 , wherein said glucose-containing composition comprises honey.

11. The method of claim 5 , wherein the glucose to cannabinoid weight/weight ratio in said cannabinoid-enriched glucose composition is greater than 10.

12. The method of claim 5 , wherein said selected temperature is in the range of between 20° C. and 70° C.

13. The method of claim 5 , including additionally blending said cannabinoid-enriched glucose composition with a non-cannabis pharmaceutical compound.

14. A pharmaceutical product comprising a therapeutic composition produced according to a method comprising:

(i) providing honey;

(ii) providing a cannabinoid-containing composition

(iii) blending said honey with said cannabinoid-containing composition to form cannabinoid-enriched honey;

(iv) activating an enzyme present in said honey by adding water to provide a selected water activity at a selected temperature, a selected pH and for a selected duration; and

(v) removing water from said cannabinoid-enriched honey, whereby an enzymatically-catalyzed conversion of at least one of glucose present in said honey and cannabinoid is produced,

wherein said temperature, pH, water activity and duration are selected to enzymatically-catalyze the conversion of at least 0.1% by weight of said glycose glucose present in said honey, said cannabinoid or both.

15. A method of treating a medical condition selected from the group consisting of post trauma syndrome disorder (PTSD), anxiety, depression, psychosis syndromes, autism, Alzheimer's disease, Parkinson disease, inflammation, spasticity and muscle tension, pain, epilepsy, stroke, traumatic brain injury, bronchial disorders, cancer, drug abuse, Huntington's disease, Dystonia, Amyotrophic lateral sclerosis (ALS), Tourette syndrome, Myasthenia gravis, sleep disorders and skin related syndromes and inflammatory bowel disease, the method comprising administering to a subject an effective amount of a pharmaceutical product according to claim 14 .

16. The method of claim 15 , wherein said pharmaceutical product has an enhanced therapeutic effect, compared with that of a composition comprising the same cannabinoids amounts prepared without applying the enzyme.